Immunoglobulin G and immunoglobulin M positivity in relation to coronavirus disease 2019 severity

dc.creatorITURBE ESQUIVEL, BRANDON;#0000-0003-1518-8176
dc.creatorConcepción Carrillo, Luis Edgar;x1357352
dc.creatorVelázquez Castro, Christian Israel;x1358330
dc.creatorMendieta Zerón, Hugo; 45175
dc.creatorITURBE ESQUIVEL, BRANDON
dc.creatorConcepción Carrillo, Luis Edgar
dc.creatorVelázquez Castro, Christian Israel
dc.creatorMendieta Zerón, Hugo
dc.date2022-08-06T01:30:57Z
dc.date2022-08-06T01:30:57Z
dc.date2022-07-31
dc.date.accessioned2022-10-13T00:29:57Z
dc.date.available2022-10-13T00:29:57Z
dc.identifier1110-2098
dc.identifierhttp://hdl.handle.net/20.500.11799/113267
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4156301
dc.descriptionObjective: The aim of this study was to evaluate the seropositivity of rapid immunoglobulin G (IgG) and immunoglobulin M tests in patients recovered from coronavirus disease 2019 (COVID‑19). Background: Rapid severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) antigen‑detection tests can give results in less than 30 min to detect SARS‑CoV‑2. Patients and methods: This case–control study was performed in Toluca, Mexico, from September to October, 2020. Rapid test was performed in patients older than 18 years who were diagnosed with COVID‑19. Quantitative data were presented as mean ± SD and qualitative in percentages. Pearson correlation was performed between the COVID‑19 clinical severity scale and the waist and BMI variables. Results: Twenty‑five patients were included (mean age, 45.24 years). Through the Pearson correlation, a positive relation was found between COVID‑19 clinical severity score and waist circumference (R2 = 0.161, P = 0.046844) and between the first and BMI (R2 = 0.157, P = 0.049918). The mean COVID‑19 clinical severity score of the patients was 23.12 ± 15.23. Sixty‑eight percent of positive results were obtained for the detection of IgG antibodies. In patients who exceed a score of 18 in clinical manifestations, all results for the detection of IgG antibodies against SARS‑COV‑2 were positive after several months. Conclusion: Patients with comorbidities had a higher predisposition to a more severe COVID‑19 disease, the highest intensity of signs and symptoms, the highest immunological response, and the highest probability of having antibodies against SARS‑COV‑2 over time.
dc.languageeng
dc.languageeng
dc.publisherMenoufia University
dc.relation35
dc.relation2
dc.rightsopenAccess
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectCoronavirus disease 2019 severity
dc.subjectImmunoglobulin G rapid test
dc.subjectImmunoglobulin M rapid test
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjectCoronavirus disease 2019 severity
dc.subjectImmunoglobulin G rapid test
dc.subjectImmunoglobulin M rapid test
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjectMEDICINA Y CIENCIAS DE LA SALUD
dc.subjectMEDICINA Y CIENCIAS DE LA SALUD
dc.titleImmunoglobulin G and immunoglobulin M positivity in relation to coronavirus disease 2019 severity
dc.titleImmunoglobulin G and immunoglobulin M positivity in relation to coronavirus disease 2019 severity
dc.typeArtículo
dc.typeArtículo
dc.typearticle


Este ítem pertenece a la siguiente institución